LYSG101: a potent chimeric lysin with therapeutic potential for combating <i>Staphylococcus aureus</i> infections
< 0.0001) in a neutropenic lung infection model. These findings support the potential of LYSG101 as a new and effective therapeutic agent for staphylococcal infections.
Authors
- Ning Gan (ORCID: https://orcid.org/0000-0001-9772-2437)
- Assaf Raz
- Mya Thandar
- Fang Tian (ORCID: https://orcid.org/0000-0002-8409-8812)
- Xiao Wen (ORCID: https://orcid.org/0000-0002-3761-1177)
- Menglin Wang (ORCID: https://orcid.org/0000-0001-6240-6856)
- Jiawen Guan
- Jie Ren
- Fuye Ma
- Guanghuai Jin
Institutions
- Precision Therapeutics (United States) (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2026-04-30
- DOI
- https://doi.org/10.1128/aac.01730-25
- Primary Topic
- Antimicrobial Peptides and Activities
- Type
- article
- Field-Weighted Citation Impact
- 0.00